Sotrovimab retains activity against SARS-CoV-2 omicron variant BQ.1.1 in a non-human primate model.
BQ.1.1
Non human primate
SARS-CoV2
Sotrovimab
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
13
03
2023
revised:
09
05
2023
accepted:
24
05
2023
medline:
8
6
2023
pubmed:
8
6
2023
entrez:
8
6
2023
Statut:
ppublish
Résumé
The SARS-CoV2 Omicron variants have acquired new Spike mutations leading to escape from the most of the currently available monoclonal antibody treatments reducing the options for patients suffering from severe Covid-19. Recently, both
Identifiants
pubmed: 37287613
doi: 10.1016/j.heliyon.2023.e16664
pii: S2405-8440(23)03871-9
pmc: PMC10228175
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e16664Informations de copyright
© 2023 Université Paris-Saclay.
Déclaration de conflit d'intérêts
The authors have declared that no conflict of interest exists.
Références
Nat Microbiol. 2022 Sep;7(9):1376-1389
pubmed: 35879526
Cell Rep Med. 2022 Dec 20;3(12):100850
pubmed: 36450283
Nat Commun. 2023 Feb 14;14(1):824
pubmed: 36788246
iScience. 2023 Apr 21;26(4):106413
pubmed: 36968074
Lancet Infect Dis. 2023 Jan;23(1):22-23
pubmed: 36410372
Nat Rev Microbiol. 2023 Feb;21(2):112-124
pubmed: 36307535
Cell Host Microbe. 2021 Sep 8;29(9):1437-1453.e8
pubmed: 34428428
Nature. 2020 Sep;585(7826):584-587
pubmed: 32698191
Nat Commun. 2021 Oct 20;12(1):6097
pubmed: 34671037
Antiviral Res. 2023 Jul;215:105638
pubmed: 37207822